Companies get creative with multi-targeted CARs at SITC, ASH

Of all the ways that CAR T cell structures are being optimized to improve efficacy in hematological cancers and make the transition to solid tumors, multi-targeting designs are emerging as some of the most promising.

A series of abstracts released ahead of two fall meetings, the American Society of Hematology (ASH) and Society for Immunotherapy of Cancer (SITC) annual conferences, highlight methods for applying dual or bispecific CAR T cell designs to solid tumors, and provide updates on clinical progress in hematological indications. ...